ClinicalTrials.gg
CompletedNCT03522012Updated Feb 26, 2019

Phase I, Pharmacokinetic, Safety and Tolerability Study in Healthy Volunteers

A Phase 1 interventional study of Tocilizumab in Pharmacokinetics, sponsored by Mycenax Biotech Inc.. Completed at 1 site in Australia. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-26.

Sponsored by Mycenax Biotech Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Sep 2018, 8 years 1 month ago, and no results have been posted to the registry.
  • Registered 5 months after the study started (first participant enrolled Oct 2017, registered Apr 2018).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
190
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a randomized, double-blind, 3-arm, parallel-group single-dose study to compare the PK, PD, safety, tolerability, and immunogenicity of LusiNEX (Mycenax tocilizumab) versus RoActemra (EU tocilizumab) and Actemra (US tocilizumab) after a single IV infusion of 4 mg/kg in healthy volunteers (hereafter referred to as subjects). The therapeutic dose of tocilizumab starts with 4 mg/kg and ranges to 12 mg/kg, considering 4 mg/kg is the lowest dose, the same has been selected for the study.

02

Conditions studied

  • Pharmacokinetics

Keywords

  • Pharmacokinetics
  • Tocilizumab
03

In context

Lead sponsor

Mycenax Biotech Inc. is the lead sponsor of 4 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Willing to provide written prior to performing study-related procedures.
  2. Healthy male or female aged between 18 to 55 years, inclusive.
  3. A between 18 to 30 kg/m2, inclusive.
  4. Medically healthy with clinically insignificant results (e.g., medical history, [ECGs], and physical examination) as judged by the Principal Investigator at Screening/Day 1 (admission to study center).
  5. All laboratory results including, but not restricted to, complete blood counts, liver function, and lipid profile should be within the normal range or clinically insignificant as judged by the Investigator at Screening/Day 1 (admission to study center). An abnormal laboratory result considered to be erroneous, may be repeated once during Screening at the discretion of the Investigator.
  6. Have systolic blood pressure ≤140 and ≥90 mmHg, diastolic blood pressure ≤90 and ≥50 mmHg, and a heart rate ≥40 and ≤100 beats per minute at Screening/Day 1 (admission to study center).
  7. Has to agree to abstain from alcohol intake 48 hours before administration of the study drug and during the inpatient period of the study.
  8. Negative urine drug screen/alcohol breathylzer test at Screening/Day 1 (admission to study center).
  9. Non-smokers or social smokers (defined as less than 10 cigarettes per week). No current use of any nicotine containing product. Cotinine levels ≤5 ng/mL.
  10. Willing to abstain from sexual intercourse or use 2 methods of (both male and female partners) as defined in the protocol for 3 months after study drug administration.

    Female subjects who are using oral hormonal contraceptives must be willing to use, with their partner, 2 methods of contraception as defined as defined in the protocol.

  11. Has to agree to not donate sperm or ova for at least 3 months after study drug administration.
  12. Subjects who are negative for surface antigen, hepatitis B core antibody, antibodies, I and II, as well as tuberculosis (TB) tests at Screening.
  13. Did not receive a blood transfusion within 4 weeks prior to study drug administration, donate 400 mL or more blood within 8 weeks prior to study drug administration or donate plasma within 4 weeks prior to study drug administration and agrees to not make blood donations, including red blood cells, plasma, , or whole blood for the duration of the study and for 3 months after study drug administration.
  14. Able to be compliant with the protocol and attend all scheduled visits.
  15. Has to agree to not consume any caffeine and/or xanthine products from 24 hours before admission to the study center until 48 hours after study drug administration.
  16. Not have consumed grapefruit and/or grapefruit containing products, Seville oranges or quinine (tonic water) from 24 hours before admission to the study center until after the last sample has been collected for the study.

Exclusion criteria

Exclusion Criteria:

  1. Volunteers with any known active current or history of recurrent bacterial, viral, fungal, mycobacterial or other infections.
  2. Have been treated with IV antibiotics for an infection within 8 weeks or oral antibiotics within 2 weeks prior to Screening.
  3. History of TB infection, active TB or latent TB infection, or recent exposure to a person with active TB.
  4. Previous exposure to therapeutic monoclonal antibodies in the past 6 months prior to Screening.
  5. History of severe allergic or anaphylactic reactions to humanized or murine monoclonal antibodies.
  6. A history of gastrointestinal, renal, hepatic, cardiovascular, or allergic disease.
  7. Evidence of active malignant disease, diagnosed within the previous 2 years (except basal cell carcinoma of the skin that has been excised and cured), or breast cancer diagnosed within the previous 2 years.
  8. Impaired liver function as determined by:

    • Serum and/or aspartate aminotransferase >1.5 x (ULN) at Screening or admission to the study center. Subjects with values between ULN and 1.5 x ULN may be included in the study if considered not clinically significant by the Investigator.
  9. Current or past history of diverticulitis or biliary obstruction.
  10. Presence of proteinuria (other than trace amounts i.e., +, ++/+++) at Screening or admission to the study center.
  11. Administration of an product in another study within 30 days or 5 half-lives of the investigational drug (whichever is longer) prior to screening, or are currently participating in another clinical study of an investigational drug, or intending to participate in another clinical study of an investigational drug before completion of all scheduled evaluations in this clinical study.
  12. Use of any prescription or over-the-counter medication (with the exception of medication in females and paracetamol) within 7 days of Screening and for the duration of participation in the study. This includes the use of any NSAIDs (including aspirin) within 28 days before study drug administration and for the duration of participation in the study.
  13. Intake of herbal drugs or dietary supplements excluding routine vitamins but including megadose (intake of 20 to 600 times the recommended daily dose) vitamin therapy within 28 days prior to study drug administration, unless agreed as not clinically relevant by the Investigator and Sponsor.
  14. Regular alcohol consumption of >14 (female subjects) or >21 (male subjects) units of alcohol per week at the time of Screening (1 unit = 150 mL of wine or 360 mL of beer or 45 mL of 40% alcohol).
  15. Failure to satisfy the Principal Investigator of fitness to participate for any other reason.
  16. Female subjects who are pregnant, trying to become pregnant, or lactating.
  17. Subjects who have a history of relevant drug or hypersensitivity to the active substance or to any of the .
  18. Inability to undergo venipuncture and/or tolerate venous access.
  19. Subjects who do not agree to use medically acceptable methods of contraception (as defined in the protocol).
  20. Involvement in the planning and/or conduct of the study (applies to the Sponsor, Contract Research Organizations, and study center staff, etc.).
  21. Subjects who are unlikely to co-operate with the requirements of the study.
  22. Any or planned vaccination within 28 days before Screening and for the duration of participation in the study.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
190 participants (actual)

Study arms

  • Experimental
    LusiNex

    4 mg/kg, single-dose IV infusion (Mycenax tocilizumab)

    Drug: Tocilizumab

  • Active comparator
    RoActemra

    4 mg/kg, single-dose IV infusion (RoActemra; tocilizumab marketed in EU )

    Drug: Tocilizumab

  • Active comparator
    Actemra

    4 mg/kg, single-dose IV infusion (Actemra; tocilizumab marketed in US)

    Drug: Tocilizumab

Interventions

  • Tocilizumab is a recombinant human monoclonal antibody of the immunoglobulin G1 subclass, directed against the IL-6 ligand specific receptor. By preventing the binding of IL-6 to its receptor, tocilizumab inhibits the biological activity of IL-6. Tocilizumab was approved by the US Food and Drug Administration (4 mg/kg with an increase to 8 mg/kg based upon clinical response) for the treatment of adult patients with moderate to severe active rheumatoid arthritis, who have had inadequate response to one or more tissue necrotizing factor (TNF) antagonist therapies. Tocilizumab is currently approved in 95 countries for the treatment of adult onset moderate to severe rheumatoid arthritis.

    Also known as: ACTEMRA

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics

    Area under concentration-time curve from time 0 (predose) extrapolated to infinity (AUC(0-∞)).

    Time frame: 2 months

Secondary outcomes

  1. Cmax

    Maximum concentration (Cmax)

    Time frame: 2 months

  2. tmax

    Time to reach maximum concentration (tmax)

    Time frame: 2 months

  3. AUC(0-t)

    Area under concentration-time curve from time 0 (predose) to the last quantifiable data point (AUC(0-t))

    Time frame: 2 months

  4. t1/2

    Terminal half-life (t1/2)

    Time frame: 2 months

  5. Vss

    Volume of distribution at steady-state

    Time frame: 2 months

  6. Vd

    Volume of distribution (Vd)

    Time frame: 2 months

  7. CL

    Systemic clearance (CL)

    Time frame: 2 months

  8. Kel

    Elimination rate constant (Kel)

    Time frame: 2 months

  9. AEs

    The Investigator will carefully monitor each subject throughout the study for any AEs (coded to preferred term and system organ class using the Medical Dictionary for Regulatory Activities \[MedDRA\])

    Time frame: 2 months

  10. antidrug antibodies

    means of the occurrence of antidrug antibodies (ADA)

    Time frame: 2 months

07

Study locations

1 site
  • Nucleus Network
    Melbourne, Victoria 3004, Australia
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2017 to primary completion in Sep 2018, 11 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2018
First posted
May 11, 2018
StartActual
Oct 17, 2017
Primary completionActual
Sep 26, 2018
CompletionActual
Dec 20, 2018
Last update
Feb 26, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 26, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03522012
Lead sponsor
Mycenax Biotech Inc.
Responsible party
Sponsor
First posted
May 11, 2018
Start date
Oct 17, 2017
Primary completion
Sep 26, 2018
Completion
Dec 20, 2018
Last update
Feb 26, 2019

Study contacts

Oscar Walsh, Dr.
principal investigator · Nucleus Network Ltd

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tocilizumab

Start the discussion